检索结果-南通市图书馆

The energy response of LaBr_(3)(Ce),LaBr_(3)(Ce,Sr),and NaI(Tl)crystals for GECAM

在线全文

学校读者我要写书评

暂无评论

Nuclear Science and Techniques 2024年第2期35卷 110-122页

作者： Pei-Yi feng Xi-Lei sun Zheng-Hua An Yong deng Cheng-Er wang Huang Jiang Jun-Jie Li Da-Li Zhang Xin-Qiao Li Shao-Lin Xiong Chao Zheng Ke Gong sheng yang Xiao-Jing Liu Min Gao Xiang-yang wen Ya-Qing liu yan-Bing xu Xiao-yun Zhao Jia-Cong Liu Fan Zhang Hong lu Particle and Astrophysics Center Institute of High Energy PhysicsChinese Academy of SciencesBeijing 100049China Key Laboratory of Particle Astrophysics Institute of High Energy PhysicsChinese Academy of SciencesBeijing 100049China University of Chinese Academy of Sciences Chinese Academy of SciencesBeijing 100049China Experimental Physics Center Institute of High Energy PhysicsChinese Academy of SciencesBeijing 100049China State Key Laboratory of Particle Detection and Electronics Institute of High Energy PhysicsChinese Academy of SciencesBeijing 100049China School of Nuclear Science and Technology University of South ChinaHengyang 421001China National Engineering Research Center for Rare Earth Grirem Advanced Materials Co.Ltd.and General Research Institute for Nonferrous MetalsBeijing 100088China

The GECAM series of satellites utilizes LaBr_(3)(Ce),LaBr_(3)(Ce,Sr),and NaI(Tl)crystals as sensitive materials for gamma-ray detectors(GRDs).To investigate the nonlinearity in the detection of low-energy gamma rays and address the errors in the calibration of the E-C relationship,comprehensive tests and comparative studies of the three aforementioned crystals were conducted using Compton electrons,radioactive sources,and mono-energetic *** nonlinearity test results of the Compton electrons and X-rays demonstrated substantial differences,with all three crystals presenting a higher nonlinearity for X/-rays than for Compton *** the LaBr_(3)(Ce)and LaBr_(3)(Ce,Sr)crystals having higher absolute light yields,they exhibited a noticeable nonlinear decrease in the light yield,especially at energies below 400 *** NaI(Tl)crystal demonstrated an"excess"light output in the 6-200 keV range,reaching a maximum"excess"of 9.2%at 30 keV in the X-ray testing and up to 15.5%at 14 keV during Compton electron testing,indicating a significant advantage in the detection of low-energy gamma ***,we explored the underlying causes of the observed nonlinearity in these *** study not only elucidates the detector responses of GECAM,but also initiates a comprehensive investigation of the nonlinearity of domestically produced lanthanum bromide and sodium iodide crystals.

关键词： LaBr_(3)(Ce)detector LaBr_(3)(Ce,Sr)detector NaI(Tl)detector GECAM Energy response Light yield nonlinearity

Searching for^(76)Ge neutrinoless double beta decay with the CDEX-1B experiment

在线全文

学校读者我要写书评

暂无评论

Chinese Physics C 2024年第10期48卷 11-22页

作者： Bing-Tao Zhang Jun-Zheng wang Li-Tao yang Qian yue Ke-Jun Kang yuan-Jing Li hai-Peng An C.Greeshma Jian-Ping Chang yun-Huan Chen Jian-Ping Cheng wen-Han Dai Zhi deng Chang-Hao Fang Xin-Ping Geng Hui Gong Qiu-Ju Guo xu-yuan Guo Li He sheng-Ming He Jin-Wei Hu Han-Xiong Huang Tu-Chen Huang hai-Tao Jia Xi Jiang S.Karmakar Hao-Bin Li Jian-Min Li Jin Li Qian-yun Li Ren-Ming-Jie Li xue-Qian Li yu-Lan Li Yi-Fan Liang Bin Liao Fong-Kay Lin Shin-Ted Lin Jia-xuan Liu Shu-Kui Liu yan-Dong Liu yu Liu yuan-yuan Liu Zhong-Zhi Liu Hao Ma yu-Cai Mao Qi-yuan Nie Jin-Hua Ning Hui Pan Ning-Chun Qi Jie Ren Xi-Chao Ruan Ze She Manoj Kumar Singh Tian-Xi sun Chang-Jian Tang Wei-You Tang yang Tian Guang-Fu wang Li wang Qing wang yu-feng wang yun-Xiang wang Henry-Tsz-King Wong Shi-Yong Wu yu-Cheng Wu Hao-yang Xing Rui xu Yin xu Tao xue yu-lu yan Nan Yi Chun-xu yu hai-Jun yu Jian-feng yue Ming Zeng Zhi Zeng feng-Shou Zhang Lei Zhang Zhen-Hua Zhang Zhen-yu Zhang Kang-Kang Zhao Ming-Gang Zhao Ji-Fang Zhou Zu-Ying Zhou Jing-Jun Zhou Key Laboratory of Particle and Radiation Imaging(Ministry of Education)and Department of Engineering Physics Tsinghua UniversityBeijing 100084 Department of Physics Tsinghua UniversityBeijing 100084 Institute of Physics Academia SinicaTaipei 11529 NUCTECH Company Beijing 100084 YaLong River Hydropower Development Company Chengdu 610051 College of Nuclear Science and Technology Beijing Normal UniversityBeijing 100875 College of Physics Sichuan UniversityChengdu 610065 School of Physics Peking UniversityBeijing 100871 Department of Nuclear Physics China Institute of Atomic EnergyBeijing 102413 Sino-French Institute of Nuclear and Technology Sun Yat-sen UniversityZhuhai 519082 School of Physics Nankai UniversityTianjin 300071 Department of Physics Banaras Hindu UniversityVaranasi 221005 Department of Physics Beijing Normal UniversityBeijing 100875

We operated a p-type point contact high purity germanium(PPCGe)detector(CDEX-1B,1.008 kg)in the China Jinping Underground Laboratory(CJPL)for 500.3 days to search for neutrinoless double beta(0νββ)decay of^(76)Ge.A total of 504.3 kg⋅day effective exposure data was *** anti-coincidence and the multi/single-site event(MSE/SSE)discrimination methods were used to suppress the background in the energy region of interest(ROI,1989–2089 keV for this work)with a factor of 23.A background level of 0.33 counts/(keV⋅kg⋅yr)was *** lower limit on the half life of^(76)Ge 0νββdecay was constrained as T_(1/2)^(0ν)>1.0×10^(23)yr(90%C.L.),corresponding to the upper limits on the effective Majorana neutrino mass:<3.2–7.5 eV.

关键词： neutrinoless double beta decay CDEX point-contact germanium detector ^(76)Ge

CEPC Technical Design Report

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed Xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves Weiming An Rui An Daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai yu Bai yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-Shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci Xiao-Jun Bi yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili deng Binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia Hua Cai wenyong Cai Wujun Cai Yijian Cai Yizhou Cai yuchen Cai haiying Cai Huacheng Cai Lorenzo Calibbi Junsong Cang Guofu Cao Jianshe Cao Antoine Chance xuejun Chang yue Chang Zhe Chang Xinyuan Chang Wei Chao Auttakit Chatrabhuti Yimin Che yuzhi Che Bin Chen Danping Chen Fuqing Chen Fusan Chen Gang Chen Guoming Chen Hua-Xing Chen Huirun Chen Jinhui Chen Ji-yuan Chen Kai Chen Mali Chen Mingjun Chen Mingshui Chen Ning Chen Shanhong Chen Shanzhen Chen Shao-Long Chen Shaomin Chen Shiqiang Chen Tianlu Chen Wei Chen Xiang Chen Xiaoyu Chen Xin Chen xun Chen xurong Chen Ye Chen Ying Chen yukai Chen Zelin Chen Zilin Chen Gang Chen Boping Chen Chunhui Chen Hok Chuen Cheng Huajie Cheng Shan Cheng Tongguang Cheng yunlong Chi Pietro Chimenti wen Han Chiu Guk Cho Ming-Chung Chu Xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui Xiaohao Cui Zhaoyuan Cui Brunella D'Anzi Ling-yun Dai Xinchen Dai xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue deng Wei-Tian deng Zhi deng Ziyan deng Bhupal Dev Tang Dewen Biagio Di Micco Ran Ding Siqin Dingl Yadong Ding haiyi Dong Jianin AGH University of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui University HefeiAnhui Applied Physics Department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu University Institute of ScienceVaranasi Bandirma Onyedi Eylul University Bandirma Beihang University Beijing Beijing Computational Science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal University Beijing Brown University ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad University Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo University Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central China Normal University WuhanHubei Central South University ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa Chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan China academy of engineering physics MianyangSichuan China building materials academy Beijing China Center of Advanced Science and Technology Beijing China Institute of Atomic Energy Beijing China Jiliang University HangzhouZhejiang China Nuclear Instrument CO. LTDBeijing China University of Geosciences Beijing China University of Geosciences WuhanHubei China University of Mining and Technology XuzhouJiangsu China West Normal University NanchongSichuan Chongqing University Department of PhysicsChongqing Chulalongkorn University Bangkok City University of Hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell University IthacaNY CPPM(AMU/IPhU&CNRS/INP) Marseille Dalian Minzu University DalianLiaoning Dalian University of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP JINR) Dubna East China University Of Science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by China,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV Linac,a 1.1 GeV Damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The Linac and Damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma(CHANCE001)

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2023年第3期8卷 1198-1207页

作者： hai-Dong Zhu hai-Liang Li Ming-sheng Huang Wei-Zhu yang Guo-wen Yin Bin-yan Zhong Jun-Hui sun Zhi-Cheng Jin Jian-Jian Chen Nai-Jian Ge wen-Bin Ding wen-Hui Li Jin-Hua Huang Wei Mu Shan-Zhi Gu Jia-Ping Li Hui Zhao Shu-Wei wen yan-Ming Lei yu-sheng Song Chun-wang yuan Wei-Dong wang Ming Huang Wei Zhao Jian-Bing Wu Song wang xu Zhu Jian-Jun Han Wei-Xin Ren Zai-Ming lu wen-Ge Xing Yong Fan hai-Lan Lin Zi-Shu Zhang Guo-Hui xu wen-Hao Hu Qiang Tu Hong-Ying Su Chuan-sheng Zheng Yong Chen xu-Ya Zhao Zhu-Ting Fang Qi wang Jin-Wei Zhao Ai-Bing xu Jian xu Qing-Hua Wu Huan-Zhang Niu Jian wang feng Dai Dui-Ping feng Qing-Dong Li Rong-Shu Shi Jia-Rui Li Guang yang hai-Bin Shi Jian-Song Ji yu-E Liu Zheng Cai Po yang yang Zhao Xiao-Li Zhu Li-Gong lu Gao-Jun Teng Center of Interventional Radiology&Vascular Surgery Department of RadiologyZhongda HospitalMedical SchoolSoutheast UniversityNanjing 210009China Department of Minimally invasive Intervention The Affiliated Cancer Hospital of Zhengzhou UniversityZhengzhou 450008China Department of Interventional Radiology the Third Affiliated HospitalSun Yat-Sen UniversityGuangzhou 510630China Department of Interventional Radiology Union Hospital of Fujian Medical UniversityFuzhou 350001China Department of Interventional Radiology Jiangsu Cancer Hospital&Jiangsu Institute of Cancer Research&The Affiliated Cancer Hospital of Nanjing Medical UniversityNanjing 210009China Department of Interventional Radiology The First Affiliated Hospital of Soochow UniversitySoochow UniversitySuzhou 215006China Hepatobiliary and Pancreatic Interventional Treatment Center Division of Hepatobiliary and Pancreatic SurgeryThe First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Interventional Radiology Eastern Hospital of Hepatobiliary SurgeryNavy Medical University(Second Military Medical University)Shanghai 200438China Department of Interventional Radiology Nantong First People’s HospitalNantong 226001China Department of Interventional Radiology Yancheng Third People’s HospitalYancheng 224008China Department of Minimally Invasive Interventional Therapy Sun YatSen University Cancer CenterGuangzhou 510060China Department of Vascular Surgery Southwest HospitalThird Military Medical University(Army Medical University)Chongqing 400038China. Department of Interventional Radiology Hunan Cancer HospitalChangsha 410031China Department of Interventional Oncology The First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510080China Department of Interventional Radiology The Hospital of Nantong UniversityNantong 226001China Department of Interventional Therapy Shanxi Tumor HospitalTaiyuan 030001China Department of Interventional Radiology Tibet Autonomous Region People’s

There is considerable potential for integrating transarterial chemoembolization(TACE),programmed death-(ligand)1(PD-[L]1)inhibitors,and molecular targeted treatments(MTT)in hepatocellular carcinoma(HCC).It is necessary to investigate the therapeutic efficacy and safety of TACE combined with PD-(L)1 inhibitors and MTT in real-world *** this nationwide,retrospective,cohort study,826 HCC patients receiving either TACE plus PD-(L)1 blockades and MTT(combination group,n=376)or TACE monotherapy(monotherapy group,n=450)were included from January 2018 to May *** primary endpoint was progression-free survival(PFS)according to modified *** secondary outcomes included overall survival(OS),objective response rate(ORR),and *** performed propensity score matching approaches to reduce bias between two *** matching,228 pairs were included with a predominantly advanced disease *** PFS in combination group was 9.5 months(95%confidence interval[CI],8.4-11.0)versus 8.0 months(95%CI,6.6-9.5)(adjusted hazard ratio[HR],0.70,P=0.002).OS and ORR were also significantly higher in combination group(median OS,19.2[16.1-27.3]vs.15.7 months[13.0-20.2];adjusted HR,0.63,P=0.001;ORR,60.1%vs.32.0%;Plus PD-(L)1 blockades and MTT could significantly improve PFS,OS,and ORR versus TACE monotherapy for Chinese patients with predominantly advanced HCC in real-world practice,with an acceptable safety profile.

关键词： hepatocellular targeted matching

A practical community-based response strategy to interrupt Ebola transmission in sierra Leone, 2014–2015

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Infectious Diseases of Poverty 2016年第1期5卷 670-679页

作者： Zhong-Jie Li wen-Xiao Tu Xiao-Chun wang Guo-Qing Shi Zun-Dong Yin hai-Jun Su Tao Shen Da-Peng Zhang Jian-Dong Li Shan Lv Chun-Li Cao Rui-Qian Xie Hong-Zhou lu Rong-Meng Jiang Zheng Cao Zhi-Jie An Lei-Lei Li Jie xu yan-wen Xiong Wei Zang Wei Zhang Hong-Wei Zhang wen-Sen Chen Hua Ling wen xu Jian Cai Huan-Jin luo xue-sheng Xing Can-Jun Zheng Qiang Wei Xin-xu Li Mei Li hai Jiang Li-Quan deng Ming-Quan Chen Xiang Huo feng xu xue-Hui Lai Xi-Chen Bai Long-Jie Ye Jian-Yi Yao wen-Wu Yin Jiao-Jin sun Lin Xiao Fu-Qiang Liu Xiao-Qiang Liu Hong-Wei Fan Zeng-Qiang Kou Ji-Kun Zhou Hao Zhang Da-Xin Ni Thomas TSamba Qun Li Hong-Jie yu yu wang Xiao-feng Liang Division of Infectious Disease Key Laboratory of Surveillance and Early-warning on Infectious DiseaseChinese Center for Disease Control and PreventionBeijingChina Public Health Emergency Center Chinese Center for Disease Control and PreventionBeijingChina National Center for AIDS/STD Control and Prevention Chinese Center for Disease Control and PreventionBeijingChina Chinese Field Epidemiology Training Program Chinese Center for Disease Control and PreventionBeijingChina National Immunization Program Chinese Center for Disease Control and PreventionBeijingChina Bureau of Disease Prevention and Control National Health and Family Planning Commission of the People’s Republic of ChinaBeijingChina National Institute for Viral Disease Control and Prevention Chinese Center for Disease Control and PreventionBeijingChina National Institute of Parasitic Disease Chinese Center for Disease Control and PreventionShanghaiChina Chinese Center for Health Education BeijingChina Department of Infectious Diseases Shanghai Public Health Clinical CenterShanghaiChina Beijing Ditan Hospital Capital Medical UniversityBeijingChina Health News BeijingChina National Institute for Communicable Disease Control and Prevention Chinese Center for Disease Control and PreventionBeijingChina Department of Training Chinese Center for Health EducationBeijingChina Center for Infectious Diseases Beijing Youan HospitalCapital Medical UniversityBeijingChina Infection Management The First Affiliated Hospital of Nanjing Medical UniversityNanjingChina Chongqing Municipal Center for Disease Control and Prevention ChongqingChina yunnan Provincial Center for Disease Control and Prevention KunmingChina Division of Infectious Disease Control and Prevention Zhejiang Provincial Center for Disease Control and PreventionHangzhouChina Guangdong Provincial Center for Disease Control and Prevention GuangzhouChina Division of Acute Infectious Disease Control and Prevention Hubei Provincial Center for Disease Control and PreventionW

Background:The Ebola virus disease spread rapidly in West Africa in 2014,leading to the loss of thousands of *** engagement was one of the key strategies to interrupt Ebola transmission,and practical community level measures needed to be explored in the field and tailored to the specific context of ***:First,community-level education on Ebola virus disease(EVD)prevention was launched for the community’s social mobilizers in six districts in Sierra Leone beginning in November ***,from January to May of 2015,in three pilot communities,local trained community members were organized to engage in implementation of EVD prevention and transmission interruption measures,by involving them in alert case report,contact tracing,and social *** epidemiological indicators of transmission interruption in three study communities were ***:A total of 6016 community social mobilizers from 185 wards were trained by holding 279 workshops in the six districts,and EVD message reached an estimated 631680 *** three pilot communities,72 EVD alert cases were reported,with 70.8%of them detected by trained local community members,and 14 EVD cases were finally *** tracing detected 64.3%of EVD *** median duration of community infectivity for the cases was 1 *** secondary attack rate was 4.2%,and no third generation of infection was *** health worker was infected,and no unsafe burial and noncompliance to EVD control measures were *** community-based measures were modeled to reduce 77 EVD cases,and the EVD-free goal was achieved four months earlier in study communities than whole country of Sierra ***: The community-based strategy of social mobilization and community engagement was effective in casedetection and reducing the extent of Ebola transmission in a country with weak health system. The successfullypractical experience to reduce the risk of Ebola transmission in the

关键词： Ebola virus disease Community engagement Health education Outbreak control

A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV) infected pneumonia(standard version)

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Military Medical Research 2020年第1期7卷 1-22页

作者： Ying-Hui Jin Lin Cai Zhen-Shun Cheng Hong Cheng Tong deng Yi-Pin Fan Cheng Fang Di Huang lu-Qi Huang Qiao Huang Yong Han Bo Hu Fen Hu Bing-Hui Li Yi-Rong Li Ke Liang Li-Kai Lin Li-Sha luo Jing Ma Lin-lu Ma Zhi-Yong Peng yun-Bao Pan Zhen-yu Pan xue-Qun Ren Hui-Min sun Ying wang yun-yun wang Hong weng Chao-Jie Wei Dong-Fang Wu Jian Xia Yong Xiong hai-Bo xu Xiao-Mei Yao yu-feng yuan Tai-sheng Ye Xiao-Chun Zhang Ying-wen Zhang Yin-Gao Zhang Hua-Min Zhang yan Zhao Ming-Juan Zhao Hao Zi Xian-Tao Zeng Yong-yan wang Xing-Huan wang 无 Center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Institute of Hospital Management Wuhan UniversityWuhan 430071China Department of Respiratory Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Pharmacy Zhongnan Hospital of Wuhan UniversityWuhan 430071China Institute of Evidence-Based Medicine and Knowledge Translation Henan UniversityKaifeng 475000China China Academy of Chinese Medical Sciences Beijing 100700China China Center for Evidence Based Traditional Chinese Medicine(CCEBTCM) Beijing 100700China Department of Critical Care Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Clinical Laboratory Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Infectious Diseases Zhongnan Hospital of Wuhan UniversityWuhan 430071China Division of Medical Affairs Zhongnan Hospital of Wuhan UniversityWuhan 430071China Division of Nursing Affairs Zhongnan Hospital of Wuhan UniversityWuhan 430071China Office of Nosocomial Infection Control Zhongnan Hospital of Wuhan UniversityWuhan 430071China Emergency Center Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Radiology Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Health Research Methods Evidenceand ImpactMcMaster UniversityHamiltonON L8S 4L8Canada Department of Traditional Chinese Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Global Health Institute Wuhan UniversityWuhan 430072China the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care(CPAM)

In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province;and then named "2019 novel coronavirus(2019-nCoV)" by the World Health Organization(WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world’s attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development;we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control(including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV.

关键词： 2019 novel coronavirus 2019-nCoV Respiratory disease Pneumonia Infectious diseases Rapid advice guideline Clinical practice guideline Evidence-based medicine

The first data release(DR1) of the LAMOST regular survey

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2015年第8期15卷 1095-1124页

作者： A-Li luo Yong-Heng Zhao Gang Zhao Li-Cai deng Xiao-Wei Liu Yi-Peng Jing Gang wang Hao-Tong Zhang Jian-Rong Shi Xiang-Qun Cui Yao-Quan Chu Guo-Ping Li Zhong-Rui Bai yue Wu yan Cai Shu-yun Cao Zi-Huang Cao Jeffrey L.Carlin hai-yuan Chen Jian-Jun Chen Kun-Xin Chen Li Chen xue-Lei Chen Xiao-yan Chen Ying Chen Norbert Christlieb Jia-Ru Chu Chen-Zhou Cui Yi-Qiao Dong Bing Du Dong-Wei Fan Lei feng Jian-Ning Fu Peng Gao xue-Fei Gong Bo-Zhong Gu yan-Xin Guo Zhan-wen Han Bo-Liang He Jin-Liang Hou Yong-Hui Hou wen Hou Hong-Zhuan Hu Ning-sheng Hu Zhong-wen Hu Zhi-Ying Huo Lei Jia Fang-Hua Jiang Xiang Jiang Zhi-Bo Jiang Ge Jin Xiao Kong xu Kong Ya-Juan Lei Ai-Hua Li Chang-Hua Li Guang-Wei Li hai-Ning Li Jian Li Qi Li Shuang Li Sha-Sha Li Xin-Nan Li yan Li Yin-Bi Li Ye-Ping Li yuan Liang Chien-Cheng Lin Chao Liu Gen-Rong Liu Guan-Qun Liu Zhi-Gang Liu wen-Zhi lu yu luo Yin-Dun Mao Heidi Newberg Ji-Jun Ni Zhao-Xiang Qi Yong-Jun Qi Shi-Yin Shen Huo-Ming Shi Jing Song Yi-Han Song Ding-Qiang Su Hong-Jun Su Zheng-Hong Tang Qing-sheng Tao yuan Tian Dan wang Da-Qi wang feng-Fei wang Guo-Min wang hai wang Hong-Chi wang Jian wang Jia-Ning wang Jian-Ling wang Jian-Ping wang Jun-Xian wang Lei wang Meng-Xin wang Shou-Guan wang Shu-Qing wang Xia wang Ya-Nan wang You wang yue-Fei wang You-Fen wang Peng Wei Ming-Zhi Wei Hong Wu Ke-Fei Wu xue-Bing Wu yu-Zhong Wu Xiao-Zheng Xing Ling-Zhe xu Xin-Qi xu yan xu Tai-sheng yan De-Hua yang hai-feng yang Hui-Qin yang Ming yang Zheng-Qiu Yao Yong yu Hui yuan hai-Bo yuan hai-Long yuan Wei-Min yuan Chao Zhai En-Peng Zhang Hua-Wei Zhang Jian-Nan Zhang Li-Pin Zhang Wei Zhang Yong Zhang yan-Xia Zhang Zheng-Chao Zhang Ming Zhao Fang Zhou xu Zhou Jie Zhu Yong-Tian Zhu Si-Cheng Zou Fang Zuo National Astronomical Observatories Chinese Academy of Sciences Department of Astronomy Peking University Shanghai Astronomical Observatory Chinese Academy of Sciences Nanjing Institute of Astronomical Optics & Technology National Astronomical ObservatoriesChinese Academy of Sciences University of Science and Technology of China Department of Physics Applied Physics and AstronomyRensselaer Polytechnic InstituteTroyNY 12180USA Department of Physics and Astronomy Earlham CollegeRichmondIN 47374USA Universitt Heidelberg Zentrum für AstronomieLandessternwarteKnigstuhl 1269117 HeidelbergGermany Department of Astronomy Beijing Normal University yunnan Observatories Chinese Academy of Sciences Purple Mountain Observatory Chinese Academy of Sciences

The Large sky Area Multi-Object Fiber Spectroscopic Telescope（LAMOST） general survey is a spectroscopic survey that will eventually cover approximately half of the celestial sphere and collect 10 million spectra of stars, galaxies and QSOs. Objects in both the pilot survey and the first year regular survey are included in the LAMOST DR1. The pilot survey started in October 2011 and ended in June 2012, and the data have been released to the public as the LAMOST Pilot Data Release in August 2012. The regular survey started in September 2012, and completed its first year of operation in June 2013. The LAMOST DR1 includes a total of 1202 plates containing 2 955 336 spectra, of which 1 790 879 spectra have observed signalto-noise ratio（SNR） ≥ 10. All data with SNR ≥ 2 are formally released as LAMOST DR1 under the LAMOST data policy. This data release contains a total of 2 204 696 spectra, of which 1 944 329 are stellar spectra, 12 082 are galaxy spectra and 5017 are quasars. The DR1 not only includes spectra, but also three stellar catalogs with measured parameters： late A,FGK-type stars with high quality spectra（1 061 918 entries）, A-type stars（100 073 entries）, and M-type stars（121 522 entries）. This paper introduces the survey design, the observational and instrumental limitations, data reduction and analysis, and some caveats. A description of the FITS structure of spectral files and parameter catalogs is also provided.

关键词： techniques: spectroscopic survey—data release—catalog

Efficacy and safety of Shenyankangfu Tablet,a Chinese patent medicine,for primary glomerulonephritis:A multicenter randomized controlled trial

在线全文

学校读者我要写书评

暂无评论

Journal of Integrative Medicine 2021年第2期19卷 111-119页

作者： Jie Wu Shu-wei Duan Hong-tao yang yue-yi deng Wei Li Ya-ni He Zhao-hui Ni Yong-li Zhan Shan Lin Zhi-yong Guo Jun Zhu Jing-ai Fang xu-sheng Liu Li-hua wang Rong wang Nian-song wang Xiao-hong Cheng Li-qun He Ping luo Shi-ren sun Ji-feng sun Ai-ping Yin Geng-ru Jiang Hong-yu Chen wen-hu Liu Hong-li Lin Meng Liang lu Ma Ming Chen Li-qun Song Jian Chen Qing Zhu Chang-ying Xing yun Li Ji-ning Gao Rong-shan Li Ying Li Hao Zhang Ying lu Qiao-ling Zhou Jun-zhou Fu Qiang He Guang-yan Cai Xiang-mei Chen Department of Nephrology Chinese People’s Liberation Army General HospitalChinese People’s Liberation Army Institute of NephrologyState Key Laboratory of Kidney Diseases(2011DAV00088)National Clinical Research Center for Kidney DiseasesBeijing 100853China Department of Nephrology First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin 300192China Department of Nephrology Longhua HospitalShanghai University of Traditional Chinese MedicineShanghai 200032China Department of Nephrology Shandong University of Traditional Chinese Medicine Affiliated HospitalJinan 250011.Shandong ProvinceChina Department of Nephrology Daping HospitalArmy Medical UniversityChongqing 400042China Department of Nephrology Renji HospitalShanghai Jiao Tong UniversityShanghai 200127China Department of Nephrology Guang’anmen HospitalChina Academy of Traditional Chinese Medical SciencesBeijing 100053China Department of Nephrology Tianjin Medical University General HospitalTianjin 300052China Department of Nephrology Changhai Hospital of ShanghaiNaval Medical UniversityShanghai 200433China Department of Nephrology West China HospitalChengdu 610083Sichuan ProvinceChina Department of Nephrology First Affiliated Hospital of Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Guangdong Provincial Hospital of Chinese MedicineGuangzhou 510120Guangdong ProvinceChina Department of Nephrology Shanxi Medical University Second Affiliated HospitalTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Shandong Provincial HospitalJinan 250021Shandong ProvinceChina Department of Nephrology and Rheumatology Affiliated Sixth People’s HospitalShanghai Jiao Tong UniversityShanghai 200233China Department of Nephrology Shaanxi Traditional Chinese Medicine HospitalXi'an 710003Shaanxi ProvinceChina Department of Nephrology Shuguang HospitalShanghai University of Traditional Chinese MedicineShanghai 200021China Department of Nephrology Jilin University Se

Background:Shenyankangfu Tablet(SYKFT)is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney ***:This trial compared the efficacy and safety of SYKFT,for the control of proteinuria in primary glomerulonephritis patients,against the standard drug,losartan ***,setting,participants and intervention:This was a multicenter,double-blind,randomized,controlled clinical *** glomerulonephritis patients,aged 18-70 years,with blood pressure≤140/90 mmHg,estimated glomerular filtration rate(eGFR)>45 mL/min per 1.73 ㎡,and 24-hour proteinuria level of 0.5-3.0 g,were recruited in 41 hospitals across 19 provinces in China and were randomly divided into five groups:SYKFT,losartan potassium 50 mg or 100 mg,SYKFT plus losartan potassium 50 mg or 100 *** outcome measu res:The primary outcome was change in the 24-hour proteinuria level,after 48 weeks of ***:A total of 735 participants were *** percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78%±2.56%(P=0.006)more than that in the losartan 50 mg group,which was 0.51%±2.54%(P=1.000)less than that in the losartan 100 mg *** with the losartan potassium 50 mg group,the SYKFT plus losartan potassium 50 mg group had a 13.39%±2.49%(Plus losartan potassium 100 mg group had a 9.77%±2.52%(P=0.001)greater reduction in urine *** a superiority threshold of 15%,neither was statistically ***,serum creatinine and serum albumin from the baseline did not change statistically *** average change in TCM syndrome score between the patients who took SYKFT(-3.00[-6.00,-2.00])and who did not take SYKFT(-2.00[-5.00,0])was statistically significant(P=0.003).No obvious adverse reactions were observed in any ***:SYKFT decreased the proteinur

关键词： Herbal medicine,Chinese Shenyankangfu Tablet Primary glomerulonephritis Randomized controlled trial Double blind Double dummy

在线全文

学校读者我要写书评

暂无评论

遗传性耳聋基因治疗临床指南

实用医院临床杂志 2024年第2期21卷 39-44页

作者：齐洁玉谈方志张李燕陆玲王洪阳李文妍刘闻闻付小龙贺祖宏丁小琼孙珊方巧军董耀东朱学伟童步升曹现宝郭敏范欣淼汪芹马璐张天虹于亚峰李永新樊建刚崔勇吴佩娜张宏征唐杰郭维维查定军叶放蕾何双八曹卫杨见明钱晓云赵宇孙敬武陈晓巍孙宇夏明王秋菊袁慧军冯永孔维佳杨仕明王海波高下李华伟徐磊柴人杰东南大学数字医学工程全国重点实验室附属中大医院耳鼻咽喉头颈外科生命科学与技术学院生命与健康高等研究院江苏省生物医学高新技术研究重点实验室江苏南京210096 南通大学神经再生联合创新中心江苏南通226001 北京理工大学航天中心医院神经内科生命学院北京10081 南京大学医学院附属鼓楼医院耳鼻喉头颈外科江苏省医学重点学科(实验室)江苏南京210008 中国人民解放军总医院耳鼻咽喉头颈外科医学部北京100853 听觉与平衡觉全国重点实验室北京100853 国家耳鼻咽喉疾病临床医学研究中心北京100853 聋病教育部重点实验室北京100853 聋病防治北京市重点实验室北京100853 复旦大学附属眼耳鼻喉科医院医学神经生物学国家重点实验室教育部脑科学前沿研究中心上海200031 复旦大学生物医学研究所上海200032 国家卫健委听觉医学重点实验室上海200031 复旦大学脑科学研究院和脑科学协同创新中心上海200032 山东大学山东省耳鼻喉医院耳鼻咽喉头颈外科山东济南250022 山东省耳鼻喉研究所山东济南250022 山东第一医科大学/山东省医学科学院医学科技创新中心山东济南250000 武汉大学中南医院耳鼻咽喉头颈外科湖北武汉430071 东南大学附属中大医院耳鼻咽喉头颈外科江苏南京210009 复旦大学附属眼耳鼻喉科医院耳鼻喉科上海200032 安徽医科大学第二附属医院耳鼻咽喉头颈外科安徽合肥230601 中国医科大学附属盛京医院耳鼻咽喉头颈外科辽宁沈阳110004 吉林大学中日联谊医院耳鼻咽喉头颈外科吉林长春130033 安徽医科大学第一附属医院耳鼻咽喉头颈外科安徽合肥230022 云南省第一人民医院耳鼻喉科云南昆明650032 昆明医科大学第一附属医院耳鼻喉科云南昆明650032 中国医学科学院北京协和医学院北京协和医院耳鼻咽喉科北京100730 中南大学湘雅二医院耳鼻咽喉头颈外科湖南长沙410008 南华大学衡阳医学院基础医学院细胞生物学与遗传学教研室细胞应激生物学衡阳市重点实验室湖南衡阳421001 哈尔滨医科大学附属第一医院黑龙江哈尔滨150001 苏州大学附属第一医院耳鼻咽喉科江苏苏州215006 首都医科大学附属北京同仁医院耳鼻咽喉头颈外科北京100730 四川省医学科学院·四川省人民医院/电子科技大学附属医院耳鼻咽喉头颈外科四川成都610072 广东省人民医院耳鼻咽喉头颈外科/广东省医学科学院/南方医科大学广东广州510080 南方医科大学珠江医院耳鼻咽喉头颈外科广东广州510282 空军军医大学西京医院耳鼻咽喉-头颈外科陕西西安710032 郑州大学第一附属医院耳科河南郑州450000 东南大学医学院附属南京同仁医院耳鼻咽喉头颈外科江苏南京211102 四川大学华西医院耳鼻咽喉头颈外科四川成都610041 中国科学技术大学附属第一医院耳鼻咽喉头颈外科安徽合肥230001 华中科技大学同济医学院附属协和医院耳鼻咽喉头颈外科湖北武汉430022 山东第一医科大学附属山东省立医院耳鼻咽喉科山东济南250021 山东省医学科学院医学科技创新中心山东济南250021 山东大学附属山东省立医院耳鼻咽喉科山东济南250021 国家卫生健康委耳鼻咽喉重点实验室山东济南250021 四川大学华西医院罕见病研究院四川成都6010041 南华大学衡阳医学院南华大学附属妇幼保健院湖南长沙410008 中南大学湘雅医院耳鼻咽喉头颈外科湖南长沙410008 上海人工耳蜗工程技术研究中心上海200031 东南大学深圳研究院广东深圳518063

遗传性耳聋是一种常见的遗传性疾病,新生儿的发病率为1‰~3‰。患者终身携带致病突变,导致不可逆性耳聋,至今尚无临床可用的治疗药物。在部分遗传性耳聋动物模型中,基因治疗已被证实为潜在有效的治疗方法。国内外已开展了多项遗传性耳... 详细信息

遗传性耳聋是一种常见的遗传性疾病,新生儿的发病率为1‰~3‰。患者终身携带致病突变,导致不可逆性耳聋,至今尚无临床可用的治疗药物。在部分遗传性耳聋动物模型中,基因治疗已被证实为潜在有效的治疗方法。国内外已开展了多项遗传性耳聋基因治疗的临床试验。其中,由东南大学附属中大医院牵头,联合国内多家医院成功开展的遗传性耳聋基因治疗临床试验,取得了显著的疗效,并积累了丰富的经验。为规范遗传性耳聋基因治疗并提供临床研究指导,全国多家医院的耳科专家讨论制定了遗传性耳聋基因治疗临床指南,内容涵盖了伦理审查、遗传性耳聋的诊断和入组标准、临床前准备、药物、疗效与安全性评估标准、术后言语康复等。本指南将为耳聋基因治疗的临床诊疗提供规范的理论和技术指导。

关键词：遗传性耳聋基因治疗临床指南